Carlumab Overview

Introduction of Carlumab

Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.

Mechanism of Action of Carlumab

Carlumab is designed to specifically target CCL2, a small cytokine of CC chemokine family. CCL2, also known as monocyte chemoattractant protein 1 (MCP-1) and small inducible cytokine A2, is a monomeric polypeptide with a molecular weight of about 13kDa. It is mainly secreted by monocytes, macrophages and dendritic cells. CCL2 is anchored in the plasma membrane of endothelial cells through the glycosaminoglycan side chain of proteoglycan. CCL2 can chemotactic monocytes macrophages and T lymphocytes affect their phagocytosis and produce antibodies to resist the physiological function of invasive microorganisms. As a potent chemokine of tumor-associated macrophages (TAM), CCL2 can indirectly promote the invasion and metastasis of tumor cells through the chemotaxis of TAM. It induces the expression of matrix metalloproteinase 2 (MMP2) and 9 in tumor cells by binding to CCR2 on tumor cells and mediates tumor cell metastasis to enhance the invasive ability of tumor cells. In addition, it has recently been found that CCL2 plays a key role in the occurrence and development of many diseases, such as tumor, central nervous system disease, immune system disease, AIDS, leukemia, diabetes and so on. Upon administration, the binding of Carlumab to CLL2, blocks the interaction between CLL2 and CCR2, resulting in the inhibition of angiogenesis and proliferation of tumor cells.

Fig 1. Mechanism of Action of Carlumab

What We Provide

Therapeutic Antibody

Carlumab

We provide high-quality Carlumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

For research use only. Not intended for any clinical use.